Measuring the Concentration of Serum Syndecan-1 to Assess Vascular Endothelial Glycocalyx Injury During Hemodialysis

Keigo Kusuzawa1†, Keiko Suzuki2†, Hideshi Okada1*, Kodai Suzuki1, Chihiro Takada1, Soichiro Nagaya1, Ryu Yasuda1, Haruka Okamoto1, Takuma Ishihara3, Hiroyuki Tomita4, Yuki Kawasaki1, Toru Minamiyama1, Ayane Nishio1, Hirotsugu Fukuda1, Takuto Shimada1, Yuto Tamaoki1, Tomoki Yoshida1, Yusuke Nakashima1, Naokazu Chiba1, Genki Yoshimura1, Ryo Kamidani3, Tomotaka Miura2, Hideaki Iiwa4, Fuminori Yamaji1, Yusuke Mizuno1, Takahito Miyake1, Yuichiro Kitagawa1, Tetsuya Fukuta1, Tomoaki Doi1, Akio Suzuki6, Takahiro Yoshida1, Nobuyuki Tetsuka2, Shozo Yoshida1,5 and Shinji Ogura1

1 Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan, 2 Department of Infection Control, Gifu University Graduate School of Medicine, Gifu, Japan, 3 Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan, 4 Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan, 5 Abuse Prevention Center, Gifu University Graduate School of Medicine, Gifu, Japan, 6 Department of Pharmacy, Gifu University Hospital, Gifu, Japan

Glycocalyx is present on the surface of healthy endothelium, and the concentration of serum syndecan-1 can serve as an injury marker. This study aimed to assess endothelial injury using serum syndecan-1 as a marker of endothelial glycocalyx injury in patients who underwent hemodialysis. In this single-center, retrospective, observational study, 145 patients who underwent hemodialysis at the Gifu University Hospital between March 2017 and December 2019 were enrolled. The median dialysis period and time were 63 months and 3.7 h, respectively. The serum syndecan-1 concentration significantly increased from 124.6 ± 107.8 ng/ml before hemodialysis to 229.0 ± 138.1 ng/ml after hemodialysis (P < 0.001). Treatment with anticoagulant nafamostat mesylate inhibited hemodialysis-induced increase in the levels of serum syndecan-1 in comparison to unfractionated heparin. Dialysis time and the change in the syndecan-1 concentration were positively correlated. Conversely, the amount of body fluid removed and the changes in the syndecan-1 concentration were not significantly correlated. The reduction in the amount of body fluid removed and dialysis time inhibited the change in the syndecan-1 levels before and after hemodialysis. In conclusion, quantitative assessment of the endothelial glycocalyx injury during hemodialysis can be performed by measuring the serum syndecan-1 concentration, which may aid in the selection of appropriate anticoagulants, reduction of hemodialysis time, and the amount of body fluid removed.

Keywords: hemodialysis, glycocalyx, syndecan-1, body fluid removal, nafamostat mesylate
INTRODUCTION

Malnutrition, inflammation, and atherosclerosis are strongly associated with each other in chronic kidney disease (1), and both a malnourished state and atherosclerosis can be caused by inflammation. Moreover, chronic microinflammation is observed in patients who undergo hemodialysis (2). Several factors, such as uremia, activation of free radicals and adhesion molecules, and hemodialysis membrane, can lead to microinflammation in patients who undergo hemodialysis (3–5). Uremic substances and the hemodialysis membrane promote the production of free radicals and cytokines by stimulating neutrophils, and the resulting inflammation further causes endothelial injury. However, there is no method to quantitatively assess endothelial cell injury.

The vascular endothelium is composed of a thin monolayer of endothelial cells, and this lines the entire circulatory system, particularly the parts that are exposed to the circulating blood. The healthy endothelium is covered by a glycoprotein called glycocalyx (6–10), which plays pivotal roles in vascular homeostasis (11, 12). The endothelial glycocalyx is degraded by several factors, such as sepsis, major surgery, trauma, ischemia/reperfusion, and prolonged hyperglycemia. Persistent and diffuse alterations in the glycocalyx are associated with widespread endothelial dysfunction, changed permeability, and impaired oxygen and nutrient delivery to the cells (11, 13, 14). Several studies have revealed the relationship between endothelial glycocalyx injury and serious diseases, such as cardiovascular disease, acute kidney injury, and chronic kidney disease (15, 16). Moreover, the structure of the endothelial glycocalyx is degraded in chronic diseases, such as aging (17), diabetes (18), and hypertriglyceridemia (19).

The glycocalyx comprises cell-bound proteoglycans, glycosaminoglycan side chains, and sialoproteins (13, 20). The proteoglycans consist of a core protein, such as a member of the syndecan protein family, to which glycosaminoglycan molecules are linked (21). Syndecan-1 is the core protein in heparan sulfate proteoglycan that is observed in the glycocalyx. It is released from the endothelium when the glycocalyx is injured, causing an increase in its concentration in circulation (22). Moreover, serum syndecan-1 has been used as an endothelial injury marker in recent clinical studies in critically ill patients (23–26).

Therefore, the present study aimed to assess endothelial injury using the serum syndecan-1 level as a marker of endothelial glycocalyx injury in patients who underwent hemodialysis. Additionally, we examined the medication type and factors that influence the concentration of syndecan-1.

METHODS

Patients

This was a single-center, retrospective, observational study conducted at the Gifu University Hospital, affiliated to Gifu University, Gifu, Japan. Patients, who underwent hemodialysis at the Gifu University Hospital between March 2017 and December 2019 and whose dry weight remained unchanged in the last three examinations, were enrolled. Patients aged <20 years, who underwent plasma apheresis, plasma exchange, and double filtration plasma therapy, and had not maintained their dry weight were excluded. Finally, data from 145 patients were obtained and analyzed (Figure 1).

Ethics Approval and Consent to Participate

The study conformed to the principles outlined in the Declaration of Helsinki (43). Ethics approval was obtained from the Medical Ethics Committee of the Gifu University Graduate
School of Medicine, Gifu, Japan (approval no.: 2021-A005). The need for informed consent from participants was waived by the medical ethics committee because of the retrospective nature of the study. Before initiation, the study was registered in the UMIN Clinical Trials Registry (registry number: UMIN000051415).

**Data Collection and Study Design**

Blood was routinely sampled before and after hemodialysis from eligible patients at the time of the last hemodialysis before being discharged from Gifu University Hospital, and data from these blood samples were used in the present study. All laboratory data (except serum syndecan-1), dry weight, and other patient demographics were extracted from the hospital’s electronic medical records. The concentration of serum syndecan-1 was measured using an enzyme-linked immunosorbent assay (950.640.192; Diacalone, Besancon, Cedex, France). The data were retrospectively analyzed. As an index of the efficiency of dialysis, Kt/V was calculated as described previously (44).

**Statistical Analysis**

The sample size in this study was calculated to obtain sufficient amount of data and conditions to avoid overfitting in multivariable regression analysis. It was necessary to collect at least 90 patients to estimate the parameters of the six covariates, including the interaction term in the multivariable regression model (45). Patients’ baseline characteristics are presented as medians and interquartile ranges for continuous variables, and as frequencies and proportions for categorical variables. For the primary analysis, a mixed effect model was used to assess the change in the syndecan-1 levels with hemodialysis. The difference in the syndecan-1 levels before and after hemodialysis in the anticoagulant subgroup was confirmed using paired t-test. A multivariable linear regression analysis was performed to compare the change in the syndecan-1 levels before/after hemodialysis and treatment with anticoagulants. The covariates in the regression model were age, sex, dry weight, and dialysis period (46). These variables were selected a priori based on previous studies. In another model, dry weight and dialysis period were simultaneously incorporated into the linear regression model to evaluate the effect of factors during dialysis on the levels of syndecan-1. An interaction term was included in the model to confirm the effect of modification of dry weight and dialysis period on changes in the levels of syndecan-1. If the interaction term was statistically significant, the effect of the dialysis period (or dry weight) on syndecan-1 was determined to be modified by dry weight (or the dialysis period). There were no missing values in the data used in the analyses. A two-sided P-value < 0.05 was considered to be statistically significant. The study was exploratory and there were concerns concerning the low statistical power; therefore, the interaction was evaluated with a two-sided P < 0.1. R version 4.1.0 was used for statistical analyses (R Foundation for Statistical Computing, Vienna, Austria).

**RESULTS**

**Characteristics of Patients**

We finally enrolled 145 patients with a median age of 66 years (Figure 1; Table 1). The median dialysis period and time were 63 months and 3 h and 45 min, respectively. The most common primary illness was diabetic nephropathy, which was observed in 37 patients (25.5%).

| TABLE 1 | Patient demographics. |
|----------|-----------------------|
| Characteristics | Median (range) or number |
| Number of cases, n | 145 |
| Age (years), mean (IQR) | 68 (60–77) |
| Sex (female/male), n (%) | 44 (30.3)/101 (69.7) |
| Dialysis period (months), median (IQR) | 20.0 (1.0–87.0) |
| Dialysis time (h), median (IQR) | 4.0 (3.0–4.0) |
| Systolic blood pressure before dialysis (mmHg), median (IQR) | 136.0 (121.0–157.0) |
| Diastolic blood pressure before dialysis (mmHg), median (IQR) | 69.0 (59.0–79.0) |
| Primary illness, n (%) | |
| Chronic glomerulonephritis | 29 (20.0) |
| Rapidly progressive glomerulonephritis | 4 (2.8) |
| Polycystic kidney disease | 8 (5.5) |
| Nephrosclerosis | 8 (5.5) |
| Diabetic nephropathy | 37 (25.5) |
| Nephritis with autoimmune disease | 6 (4.1) |
| Renal/urological tumor | 5 (3.4) |
| Obstructive urinary tract/urination disorders | 1 (0.7) |
| Paraproteinemia (myeloma) | 1 (0.7) |
| Acute kidney injury | 10 (6.9) |
| Congenital anomalies of the kidney and urinary tract | 1 (0.7) |
| Unknown | 33 (22.8) |
| Others | 2 (1.4) |
| Hemodialysis type, n (%) | |
| HD | 133 (91.7) |
| HDF | 12 (8.3) |
| Vascular access type, n (%) | |
| Arteriovenous fistula | 107 (73.8) |
| Arteriovenous graft | 8 (5.5) |
| Temporary vascular catheter | 23 (15.9) |
| Permanent vascular catheter | 7 (4.8) |
| Dialysis efficiency | |
| Kt/V | 1.20 (0.06–1.86) |
| Medication, n (%) | |
| Low-molecular-weight heparin | 24 (16.6) |
| Nafamostat mesylate | 20 (13.8) |
| Dialysis membrane, n (%) | |
| Polysulfonate | 110 (75.9) |
| Polysulfobetaine | 34 (23.4) |
| Asymmetric triacetate | 1 (0.7) |

HD, hemodialysis; HDF, hemodiafiltration; IQR, interquartile range.
The number of patients who underwent hemodialysis and hemodiafiltration was 133 (91.7%) and 12 (8.3%), respectively. Anticoagulation agents, such as unfractionated heparin, low-molecular-weight heparin, and nafamostat mesylate, were administered to 101, 24, and 20 patients, respectively. The median Kt/V-value, an index of dialysis efficiency, was 1.20.

**Concentration of Serum Syndecan-1 and Hemodialysis**

The concentrations of serum syndecan-1 before and after hemodialysis were 124.6 ± 107.8 and 229.0 ± 138.1 ng/ml, respectively; this indicated that the serum syndecan-1 concentration significantly increased ($P < 0.001$) after hemodialysis (Table 2).

| Status          | SDC-1 concentration (ng/ml) | $P$-value |
|-----------------|----------------------------|-----------|
| Before HD       | 124.6 ± 107.8              | <0.001    |
| After HD        | 229.0 ± 138.1              |           |

SDC-1, syndecan-1; HD, hemodialysis. $P$-values were obtained from a mixed-effects model.

SDC-1, syndecan-1; HD, hemodialysis. $^*$Statistically significant ($P < 0.05$).

The concentration of serum syndecan-1 significantly increased after hemodialysis in patients who received unfractionated heparin and low-molecular-weight heparin; however, the concentration of syndecan-1 was not significantly different before and after hemodiagnosis in those who received nafamostat mesylate (Table 3).

**TABLE 3 | Serum SDC-1 concentration before and after hemodialysis.**

| Status          | SDC-1 concentration (ng/ml) | $P$-value |
|-----------------|----------------------------|-----------|
| Before HD       | 124.6 ± 107.8              | <0.001    |
| After HD        | 229.0 ± 138.1              |           |

The relationship between the concentration variability of syndecan-1 and the dialysis condition, including the dialysis time and the amount of body fluid removed, was confirmed. The amount of body fluid removal was corrected by the dry weight. The dialysis time and change in concentration of syndecan-1 showed a positive correlation ($P = 0.033$), but there was no significant association ($P = 0.111$) between the amount of body fluid removed and the syndecan-1 concentration changes (Table 5).

Next, we examined the modifying effect of the amount of body fluid removed on the association between the change in the concentration of syndecan-1 and dialysis time. The change in the syndecan-1 concentration before and after hemodialysis increased with respect to enhanced removal of body fluids and prolonged dialysis time ($P$ for interaction = 0.063, Figure 2). However, the change in the syndecan-1 concentration before and after hemodialysis decreased with respect to a decrease in the amount of body fluid removed and shortened dialysis time.

**DISCUSSION**

The present study revealed the following: (a) the endothelial glycocalyx may be injured during hemodialysis; (b) endothelial glycocalyx injury may be attenuated by administering nafamostat mesylate as an anticoagulant; and (c) endothelial glycocalyx injury may be aggravated by an increase in the amount of body fluid removed and prolonged dialysis time.

A previous study reported that the serum syndecan-1 concentration was approximately 20 ng/ml in healthy individuals (19); in contrast, in this study, it was found to be 124.6 ± 107.8 ng/ml in patients who underwent hemodialysis. This result confirmed that the endothelial glycocalyx sustained injuries in patients who underwent hemodialysis, consistent with the findings of a previous report (27). This indicates that endothelial glycocalyx injury may be aggravated by an increasing fluid volume.

Moreover, the serum syndecan-1 concentration increased after hemodialysis compared to the corresponding value before hemodialysis. This finding suggested that the endothelial glycocalyx was injured during hemodialysis, probably because of the production of free radicals and cytokines during this procedure.

During hemodialysis, unfractionated heparin, low-molecular-weight heparin, and nafamostat mesylate were used as anticoagulating agents. Low-molecular-weight heparin and nafamostat were administered to patients that had any disease that was associated with bleeding tendencies. Our results suggested that an increase in the syndecan-1 concentration was attenuated in patients who received nafamostat mesylate.

Nafamostat mesylate, a synthetic serine protease inhibitor, is a short-acting anticoagulant (28), and is also used during hemodialysis to prevent proteolysis of fibrinogen into fibrin (29). It is a slow, tight-binding substrate that traps the target protein in the acyl-enzyme intermediate form and inhibits enzyme activity (30, 31). It was previously reported that nafamostat mesylate can inhibit the kallikrein-kinin system, which promoted vascular permeability via the produced bradykinin (32–34). In addition, nafamostat has been recently identified as a potential therapy...
TABLE 4 | Results of multivariable regression analysis between anticoagulants.

| Anticoagulants                                      | Coefficient* | 95% LCL  | 95% UCL  | P-value |
|----------------------------------------------------|--------------|----------|----------|---------|
| Low-molecular-weight heparin vs. unfractionated heparin | −18.07       | −56.776  | 20.637   | 0.358   |
| Nafamostat mesylate vs. unfractionated heparin     | −116.473     | −158.442 | −74.504  | <0.001  |
| Nafamostat mesylate vs. low-molecular-weight heparin | −98.403      | −150.482 | −45.324  | <0.001  |

LCL, lower confidence limit; UCL, upper confidence limit.

*Coefficients from the multivariable linear regression model adjusted for age, sex, dry weight, and dialysis period, shown as differences in the serum syndecan-1 concentration for low-molecular-weight heparin vs. unfractionated heparin, nafamostat mesylate vs. unfractionated heparin, and nafamostat mesylate vs. low-molecular-weight heparin, respectively.

TABLE 5 | Relationship between syndecan-1 concentration variability and dialysis conditions.

| Factors                                      | Coefficient* | 95% LCL  | 95% UCL  | P-value |
|----------------------------------------------|--------------|----------|----------|---------|
| Body fluid removed/dry weight (per 0.01 L/kg increase) | 9.107        | 0.144    | 18.07    | 0.111   |
| Dialysis time (per 1 min increase)           | 23.349       | −8.836   | 55.533   | 0.033   |

LCL, lower confidence limit; UCL, upper confidence limit.

*Coefficients from the multivariable linear regression model adjusted for age, sex, and dialysis period, shown as increment in the serum syndecan-1 concentration for a unit change in factors.

Against the coronavirus disease (35). Infection with severe acute respiratory syndrome coronavirus 2 induces endotheliitis due to viral involvement and inflammatory response of the host and, thus, it is associated with endothelial glycocalyx injury (21). Therefore, nafamostat mesylate may have a beneficial effect on the endothelial glycocalyx, although this is supported only by circumstantial evidence.

Extension of dialysis time is a strategy to improve prognosis (36); however, it remains controversial (36, 37). The present study identified that changes in the serum syndecan-1 levels are small in patients who have prolonged dialysis time and slow removal of body fluid. Therefore, these two strategies could prevent endothelial glycocalyx injury. Several reports have also revealed that prolonged hemodialysis was associated with improved blood pressure and fluid management (38–40). Additionally, rapid removal of body fluid is associated with a greater risk of mortality and cardiovascular events (41). Moreover, hypotension during hemodialysis is also associated with higher mortality (42).

These mechanisms may explain how lower ultrafiltration rates with prolonged hemodialysis and slow removal of body fluids may ameliorate endothelial vascular permeability via attenuation of endothelial glycocalyx injury. Therefore, we propose that slow removal of body fluids with prolonged hemodialysis can reduce hypotension during hemodialysis.

This study had some limitations. First, the hemodialysis time in most patients was <4 h. Therefore, an accurate examination of prolonged hemodialysis could not be performed. Second, less types of dialyzer were used in the present study. Third, in this study, other biomarkers of glycocalyx injury, such as the serum hyaluronan and hyaluronidase levels, were not measured. Although further studies are required, measuring the concentration of serum syndecan-1 may help assessing endothelial injury under low blood flow (e.g., chronic hemodiafiltration) and membrane compatibility by using a different type of dialyzer. Moreover, the serum syndecan-1 level is proposed to be a useful biomarker for daily monitoring of organ dysfunction, and may be an important risk factor for mortality in critically ill patients (25).

In conclusion, the study presented a method for the quantitative assessment of endothelial glycocalyx injury by measuring the concentration of serum syndecan-1 during hemodialysis. Although hemodialysis causes endothelial glycocalyx injury, it may be mitigated by maintenance of hemodialysis duration and by modulation of the amount of body fluid removed via the quantitative assessment of the serum syndecan-1 level.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Ethics approval was obtained from the Medical Ethics Committee of the Gifu University Graduate School of Medicine, Gifu, Japan (record no.: 2021-A005). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

KK and HOkad wrote the manuscript. KK, KoS, SN, HOkam, GY, RK, and TMiu collected the blood samples. FY, HOi, CT, YKa, TMin, AN, HF, TS, YT, ToY, YN, and NC measured the syndecan-1 concentration using ELISA. KeS and RY created the database. TI performed a statistical analysis. YM, TMiy, YKi, TF, TD, and TaY treated the patients. HT, SY, and SO supervised the study. HOkad and AS revised and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Ministry of Education, Science and Culture of Japan grants-in-aid for scientific research (grant numbers 19H03756; HOkad, 19K18347; TF, 19K09410; TD, and 18K16511; SY).

ACKNOWLEDGMENTS

The authors would like to thank the paramedical crew who shared the data obtained by them with us and allowed us to use the data for the writing of this report. The authors also thank Editage (www.editage.com) for English language editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.791309/full#supplementary-material

REFERENCES

1. Stenvinkel P, Heimburger O, Paultre F, Diczfalussy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. (1999) 55:1899–911. doi: 10.1046/j.1523-1755.1999.00422.x
2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. (1999) 55:648–58. doi: 10.1046/j.1523-1755.1999.00273.x
3. Kultz D. Hyperosmolality triggers oxidative damage in kidney cells. Proc Natl Acad Sci USA. (2004) 101:1977–8. doi: 10.1073/pnas.0403241101
4. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int. (2004) 66:1099–106. doi: 10.1111/j.1523-1755.2004.00860.x
5. Kawabata K, Nakai S, Miwa M, Sugira T, Otsuka Y, Shinzato T, et al. CD31 expression on leukocytes is downregulated during hemodialysis. Neprhon. (2001) 89:153–60. doi: 10.1159/0000046062
6. Ando Y, Okada H, Takemura G, Suzuki K, Takada C, Tomita H, et al. Brain-specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain barrier. Sci Rep. (2018) 8:17523. doi: 10.1038/s41598-018-35976-2
7. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. (2010) 105:687–701. doi: 10.1007/s00395-010-0118-z
8. Inagawa R, Okada H, Takemura G, Suzuki K, Takada C, Yano H, et al. Ultrastructural alteration of pulmonary capillary endothelial glycocalyx during endotoxemia. Chest. (2018) 154:317–25. doi: 10.1016/j.chest.2018.03.003
9. Okada H, Takemura G, Suzuki K, Oda K, Takada C, Hotta Y, et al. Three-dimensional ultrastructure of capillary endothelial glycocalyx under normal and experimental endotoxin conditions. Crit Care. (2017) 21:261. doi: 10.1186/s13054-017-1841-8
10. Rehm M, Zahler S, Lötisch M, Welsch U, Conzen P, Jacob M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology, (2004) 100:1211–23. doi: 10.1097/00000542-200405000-00025
11. Chelazzi C, Villa G, Mancinelli P, De Gaudio AR,adem. C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. (2015) 19:26. doi: 10.1186/s13054-015-0741-z
12. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. (2012) 108:364–94. doi: 10.1093/bja/aer515
13. Saladon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol. (2012) 226:562–74. doi: 10.1002/path.3964
14. Henrich M, Gruss M, Weigand MA. Sepsis-induced degradation of endothelial glycocalix. ScientificWorldJournal. (2010) 10:917–23. doi: 10.1100/tsw.2010.88
15. Liborío AR, Brazi MB, Seguro AC, Meneses GC, Neves FM, Pedroza DC, et al. Endothelial glycocalyx damage is associated with leptospirosis acute kidney injury. Am J Trop Med Hyg. (2015) 92:611–6. doi: 10.4269/ajtmh.14-0232
16. Padberg JS, Wiesinger A, di Marco GS, Reuter S, Grabner A, Kentrup D, et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis. (2014) 234:335–43. doi: 10.1016/j.atherosclerosis.2014.03.016
17. Machin DR, Bloom SI, Campbell RA, Phuong TT, Gates PE, Lesniewski LA, et al. Advanced age results in a diminished endothelial glycocalyx. Am J Physiol Heart Circ Physiol. (2018) 315:H531–9. doi: 10.1152/ajpheart.00104.2018
18. Nieuworp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. (2006) 55:480–6. doi: 10.2337/diabetes.55.02.06/db05-1103
19. Oda K, Okada H, Suzuki A, Tomita H, Kobayashi R, Sumi K, et al. Factors enhancing serum syndecan-1 concentrations: a large-scale comprehensive medical examination. J Clin Med. (2019) 8:1320. doi: 10.3390/jcm8091320
20. Paulus P, Jennenewin C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers. (2011) 16:511–21. doi: 10.3109/1354750X.2011.587893
21. Okada H, Yoshida S, Hara A, Ogura S, Tomita H. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection. Microcirculation. (2021) 28:e12654. doi: 10.1111/micc.12654
22. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular
surgery with global and regional ischemia. Circulation. (2007) 116:1896–906. doi: 10.1161/CIRCULATIONAHA.106.684852

23. Ostrowski SR, Haase N, Müller RB, Meller MH, Pott FC, Perner A, et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care. (2015) 19:191. doi: 10.1186/s13054-015-0918-5

24. Puskarich MA, Cornelius DC, Tharp J, Nandi U, Jones AE. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J Crit Care. (2016) 36:125–9. doi: 10.1016/j.jcrc.2016.06.027

25. Suzuki K, Okada H, Sumi K, Tomita H, Kobayashi R, Ishihara T, et al. Serum syndecan-1 reflects organ dysfunction in critically ill patients. Sci Rep. (2021) 11:8864. doi: 10.1038/s41598-021-88303-7

26. Suzuki K, Okada H, Tomita H, Sumi K, Kakino Y, Yasuda R, et al. Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury. Thromb J. (2021) 19:5. doi: 10.1186/s12959-021-00258-x

27. Berg S, Golster M, Lisander B. Albumin extravasation and tissue washout of hyaluronan after plasma volume expansion with crystalloid or hypocoiontcolloid solutions. Acta Anaesthesiol Scand. (2002) 46:166–72. doi: 10.1034/j.1399-6576.2002.460207.x

28. Al-Horani RA, Desai UR. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev. (2014) 34:1168–216. doi: 10.1002/med.21315

29. Sadahiro T, Yuzawa H, Kimura T, Oguchi M, Morito T, Mizushima S, et al. Effects of antiplatelet drugs on platelet function during hemodialysis. Thromb Res. (2018) 196:209–14. doi: 10.1016/j.thromres.2018.06.049

30. Ramjee MK, Henderson IM, McLaughlin SB, Padova A. The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin. Thromb Res. (2000) 98:559–69. doi: 10.1016/S0049-3848(00)00206-1

31. Ramjee MK, Patel S. Continuous-flow injection microfluidic thrombin assays: kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin. Thromb Res. (2000) 98:559–69. doi: 10.1016/S0049-3848(00)00206-1

32. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. (1981) 661:342–5. doi: 10.1016/S0005-2744(81)90023-1

33. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. (1985) 15:164–8. doi: 10.1159/000121519

34. Paques EP, Romisch J. Comparative study on the in vitro effectiveness of antithrombotic agents. Thromb Res. (1991) 64:11–21. doi: 10.1016/0049-3848(91)90201-7

35. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. doi: 10.1038/s41422-020-0282-0

36. Chertow GM, Levin NW, Beck GJ, Daugirdas JT, Eggers PW, Kliger AS, et al. Long-term effects of frequent in-center hemodialysis. J Am Soc Nephrol. (2016) 27:1830–6. doi: 10.1681/ASN.2015040426

37. Rocco MV, Daugirdas JT, Greene T, Lockridge RS, Chan C, Pierrotos A, et al. Long-term effects of frequent nocturnal hemodialysis on mortality: the Frequent Hemodialysis Network (FHN) nocturnal trial. Am J Kidney Dis. (2015) 66:459–68. doi: 10.1053/ajkd.2015.02.351

38. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. (2009) 4:1925–31. doi: 10.2215/CJN.04470709

39. Lacson E Jr, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, et al. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol. (2012) 23:687–95. doi: 10.1681/ASN.2011070674

40. Ok E, Duman S, Asci G, Tumuklu M, Onen Serto O, Kayikcioglu M, et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-center haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant. (2011) 26:1287–96. doi: 10.1093/ndt/ggt724

41. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. (2011) 79:250–7. doi: 10.1038/ki.2010.383

42. Flythe JE, Xue H, Lynch KE, Curran GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. (2015) 26:724–34. doi: 10.1681/ASN.2014020222

43. Rickham PP. Human experimentation. Code of ethics of the World Medical Association Declaration of Helsinki. Br Med J. (1964) 2:177

44. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. (1993) 4:1205–13. doi: 10.1681/ASN.1993v04n4p1205

45. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. New York, NY: Springer. (2014). doi: 10.1007/978-1-4922-4402-0

46. Koch J, Idzerda NMA, Ettema EM, Kuipers J, Dam W, van den Born J, et al. An acute rise of plasma Na(+) concentration associates with syndecan-1 shedding during hemodialysis. Am J Physiol Renal Physiol. (2020) 319:F171–7. doi: 10.1152/ajprenal.00050.2020

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kusuzawa, Suzuki, Okada, Suzuki, Takada, Nagaya, Yasuda, Okamoto, Ishihara, Tomita, Kawasaki, Minamiyama, Nishio, Fukuda, Shimada, Tamui, Yoshida, Nakashima, Chiba, Yoshinara, Kamidani, Misra, Oiwa, Yamaji, Mizuno, Miyake, Kitagawa, Fukuta, Doi, Suzaki, Yoshida, Tetsuka, Yoshida and Ogura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.